PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50125C00017Development of cd388 as a long-lasting — Cidara Therapeutics Inc

Cidara Therapeutics Inc holds $58.1M across 1 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Sep 29, 2027 PoP end — agencies typically plan 12–18 months ahead.

Barda - Aspr / Daappo / Barda Dcma
Awarding office
Cidara Therapeutics Inc
Recipient
Sep 29, 2027
PoP end
$58.1M
Obligated
541714
NAICS
AN14
PSC
NONE
Set-aside
1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

NONE
Contract number75A50125C00017
AgencyBarda - Aspr / Daappo / Barda Dcma
Awarding officeBarda - Aspr / Daappo / Barda Dcma
IncumbentCidara Therapeutics Inc
UEIFKP3JZ9RUNY9
NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAN14
Place of performanceSAN DIEGO, CA
PoP end (current)Sep 29, 2027
PoP end (w/ options)Jul 3, 2030
Obligated$58.1M

DEVELOPMENT OF CD388 AS A LONG-LASTING PROPHYLACTIC ANTI-VIRAL OPTION FOR PROTECTION AGAINST THE HEALTH IMPACTS CAUSED… is a federal NONE award for Barda - Aspr / Daappo / Barda Dcma held by Cidara Therapeutics Inc. Estimated value $58.1M ($58.1M obligated). Current period of performance ends Sep 29, 2027 (potential Jul 3, 2030). Last award drew 1 bidder. Place of performance: SAN DIEGO, CA.

DEVELOPMENT OF CD388 AS A LONG-LASTING PROPHYLACTIC ANTI-VIRAL OPTION FOR PROTECTION AGAINST THE HEALTH IMPACTS CAUSED BY INFLUENZA

Recompete timing

Public
● Expiring in 367 days

Current PoP ends Sep 29, 2027 (367 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.

Bonuses end Sept 30

Want the durability read on 75A50125C00017? One Pursuit Analysis, $500, inside 48 business hours.

  • 48 business hours
  • $500
  • Credits toward the Pack
Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Cidara Therapeutics Inc — $58.1M obligated across 1 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)
Department of Health and Human Services (HHS)$58.1M · 100% of firm total
Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract 75A50125C00017?

75A50125C00017 (Development of cd388 as a long-lasting) is a Barda - Aspr / Daappo / Barda Dcma award with an estimated value of $58.1M, currently held by Cidara Therapeutics Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50125C00017?

Barda - Aspr / Daappo / Barda Dcma awarded 75A50125C00017 to Cidara Therapeutics Inc.

Who is the incumbent on 75A50125C00017?

Cidara Therapeutics Inc is the incumbent with $58.1M across 1 related awards in SCOUT’s public footprint. The current period of performance ends Sep 29, 2027.

When does Cidara Therapeutics Inc’s 75A50125C00017 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 29, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 75A50125C00017? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75A50125C00017